The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers
Open accessAbstract
Estrogens and androgens are instrumental in the maturation of many hormone-dependent cancers. Consequently, the enzymes involved in their synthesis are cancer therapy targets. One such enzyme, steroid sulfatase (STS), hydrolyses estrone sulfate, and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone respectively. These are the precursors to the formation of biologically active estradiol and androstenediol. This review focuses on three aspects of STS inhibitors: 1) chemical development, 2) biological activity, and 3) clinical trials. The aim is to discuss the importance of estrogens and androgens in many cancers, the developmental history of STS inhibitor synthesis, the potency of these compounds in vitro and in vivo and where we currently stand in regards to clinical trials for these drugs. STS inhibitors are likely to play an important future role in the treatment of hormone-dependent cancers. Novel in vivo models have been developed that allow pre-clinical testing of inhibitors and the identification of lead clinical candidates. Phase I/II clinical trials in postmenopausal women with breast cancer have been completed and other trials in patients with hormone-dependent prostate and endometrial cancer are currently active. Potent STS inhibitors should become therapeutically valuable in hormone-dependent cancers and other non-oncological conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“including STX64, which was effective in blocking synthesis in endometrial cancer cells in vitro.”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“The potential of STS inhibition has been evaluated in promising clinical trials (Geisler et al., 2011, Purohit and Foster, 2012, Thomas and Potter, 2015).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Purohit and Foster, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“…breast, prostate, and endometrial, initially rely on steroid production for growth: only later in development do they usually become steroid-independent with the exception of prostate cancer which can remain androgen dependent even at late-stage (Knudsen & Penning 2010, de Bono et al. 2011).”
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,323
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,255
Endogenous Hormones and Breast Cancer Risk
Bernstein, L., & Ross, R. K. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036116 · Cited by 697
Environmental causes of cancer: endocrine disruptors as carcinogens
Soto, A. M., & Sonnenschein, C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.87 · Cited by 574
Kroboth, P. D., Salek, F. S., Pittenger, A. L., Fabian, T. J., & Frye, R. F. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007903 · Cited by 530
Steroid sulfatase: molecular biology, regulation, and inhibition
Reed, M. J., Purohit, A., Woo, L. W. L., Newman, S. P., & Potter, B. V. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0003 · Cited by 524
Self-citationSulfonation and molecular action
Strott, C. A. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0040 · Cited by 487
van Landeghem, A. A. J., Poortman, J., Nabuurs, M., & Thijssen, J. H. H. (1985) · PubMed · Cited by 448
MacDonald, P. C., Edman, C. D., Hemsell, D. L., Porter, J. C., & Siiteri, P. K. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90287-9 · Cited by 440
Research works printed but not linked: 22
- 1984, Acta obstetricia et gynecologica Scandinavica, 123, 125
- 1993, Cancer Research, 53, 289
- Falany, 1996, Cancer Research, 56, 1551
- 2002, Breast cancer research and treatment, 74, 16776
- 1973, 21, 647
- 1997, 62, 346
- 2007, ORGANIC AND BIOMOLECULAR CHEMISTRY, 21, 2940
- 1980, PROGRESSION IN CANCER RESEARCH THERAPY, 14, 471
- 1987, 50, 269
- James, 2001, Endocrinology, 142, 1497, 10.1210/en.142.4.1497 · DOI
- 1955, Journal of Endocrinology, 13, 9
- 1993, 58, 106
- 1995, 60, 299
- 1998, 63, 423
- Maltais, 2011, 76, 929
- Pasqualini, 1996, Journal of Clinical Endocrinology & Metabolism, 81, 1460, 10.1210/jc.81.4.1460 · DOI
- 1995, International journal of cancer. Journal international du cancer, 62, 106
- Purohit, 1996, Cancer Research, 56, 4950
- Purohit, 2000, Cancer Research, 60, 3394
- 1993, Endocrine-Related Cancer, 45, 51
- 1984, Journal of Clinical Endocrinology & Metabolism, 54, 29
- van Landeghem, 1985, Cancer Research, 45, 2900
Cited by
Sorted by citations
Thakur, A., Singla, R., & Jaitak, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.010 · Cited by 491
Schiffer, L., Barnard, L., Baranowski, E. S., Gilligan, L. C., Taylor, A. E., Arlt, W., Shackleton, C. H. L., & Storbeck, K.-H. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105439 · Cited by 450
“STS activity is upregulated in several steroid-dependent cancers [40] and has been evaluated as drug target [170,171].”
The Regulation of Steroid Action by Sulfation and Desulfation
Mueller, J. W., Gilligan, L. C., Idkowiak, J., Arlt, W., & Foster, P. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1036 · Cited by 419
Self-citationAndrogens in pregnancy: roles in parturition
Makieva, S., Saunders, P. T. K., & Norman, J. E. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu008 · Cited by 232
Intracrine androgen biosynthesis, metabolism and action revisited
Schiffer, L., Arlt, W., & Storbeck, K.-H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.016 · Cited by 217
“The potential of STS inhibition has been evaluated in promising clinical trials (Geisler et al., 2011; Purohit and Foster, 2012; Thomas and Potter, 2015).”
Metadata
- Authors
- Purohit, A., & Foster, P. A.
- Affiliations
- Hammersmith Hospital (GB)
- ORCID
- Foster, Paul A
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2011-08-22
- Volume
- 212
- Issue
- 2
- Pages
- 99-110
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2143089038
- Cited by
- 126
- References
- 105
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 12 · 2018: 11 · 2017: 11 · 2016: 14 · 2015: 12 · 2014: 16 · 2013: 11 · 2012: 6
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Ipsen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- steroid sulfatase inhibitors, steroid sulfatase, estrone sulfate, dehydroepiandrosterone sulfate, hormone-dependent tumors, breast cancer, prostate cancer, endometrial cancer, estrogen metabolism, androgen metabolism, drug development, clinical trials, postmenopausal women
- MeSH terms
- Androgens, Animals, Breast Neoplasms, Enzyme Inhibitors, Estrogens, Female, Humans, Male, Neoplasm Proteins, Neoplasms, Hormone-Dependent, Prostatic Neoplasms, Receptors, Androgen, Receptors, Estrogen, Antineoplastic Agents, Hormonal, Steryl-Sulfatase, Aromatase Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
